NCT05985291终止不适用
BurstDRTM Spinal Cord Dorsal Column Stimulation for Painful Diabetic Neuropathy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Average change from baseline to 3 months in treatment responder rates
研究概览
简要总结
This study aims to demonstrate treatment outcomes of Painful Diabetic Neuropathy (PDN) patients treated with BurstDRTM Spinal Cord Dorsal Column Stimulator (SCS) along with conservative medical management per standard of care.
详细描述
In this study, we aim to systematically collect real world, observational and prospective data on the safety and effectiveness of an SCS system for the management of PDN. This study will provide, to the best of our knowledge, the first clinical, real world, prospective data in treatment of PDN with an SCS system.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of lower extremity Painful Diabetic Neuropathy (PDN) with symptoms for at least a year prior to signing the consent form
- •PDN refractory to FDA approved medications: duloxetine, pregabalin, tapentadol, and capscaicin
- •Lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS)
- •HbA1c ≤10%
- •BMI <45 kg/m2
- •Be 22 years of age or older at the time of enrollment
- •Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician
- •Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English
- •Be willing and capable of giving informed consent
- •Be willing and able to comply with study-related requirements, procedures, and scheduled visits
- •Have adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator
- •Be on a stable analgesic regimen, as determined by the Investigator, for at least 30 days prior to assessing pain intensity, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device
- •Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator
排除标准
- •Current daily opioid dosage greater than 120 mg morphine equivalents
- •Have an average pain intensity of ≥ 3 out of 10 cm on the VAS in the upper extremities due to diabetic neuropathy at enrollment
- •Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia and tibial or peroneal neuropathies), have had a lower limb amputation other than toes due to diabetes, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs.
- •Have a current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury, as determined by the Investigator
- •Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure, as determined clinically by the Investigator
- •Be benefitting from an interventional procedure and/or surgery to treat lower limb pain (Subjects should be enrolled at least 30 days from last benefit).
- •Have an existing intrathecal pain pump and/or another active implantable device such as a pacemaker
- •Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with ProclaimTM system guidelines in the Physician's Manual
- •Have either a metastatic malignant neoplasm or untreated local malignant neoplasm
- •Have a life expectancy of less than one year
- •Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs
- •Be concomitantly participating in another clinical study
- •Be involved in an injury claim under current litigation
- •Be a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to chronic pain
- •Have a pending or approved worker's compensation claim
- •Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome, as determined by a psychologist in the last 12 months
结局指标
主要结局
Average change from baseline to 3 months in treatment responder rates
时间窗: 3 months
Responder is defined as a subject who has at least 50% reduction in lower limb pain from baseline as measured by a 10 cm Visual Analog Scale (VAS).
次要结局
- Average change from baseline to 6 months in treatment responder rates assessed by Visual Analog Scale (0-10 cm)(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effect of Spinal Cord Stimulation in Painful Diabetic PolyneuropathyDiabetic NeuropathiesNCT00802022Maastricht University Medical Center15
Unknown
不适用
Effect of Spinal Cord Stimulation (SCS) in Painful Diabetic PolyneuropathyDiabetic NeuropathiesPainElectric Stimulation TherapyNCT01162993Maastricht University Medical Center40
已完成
不适用
Treatment for Painful Diabetic NeuropathyPainful Diabetic NeuropathyNCT05937984McMaster University20
已完成
3 期
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)Diabetic Peripheral NeuropathyNCT01474772Pfizer's Upjohn has merged with Mylan to form Viatris Inc.217
已完成
不适用
Electrical Stimulation in Diabetic Peripheral NeuropathyNMESControlNCT02082145Imperial College London14